SER-101 is a formulation of recombinant human HspB5. Previously known as DC-TAB (Clinical trial ID: NCT02442557).

​

​

How does it work?

Large HspB5 multimeric structures preferentially bind to myeloid cells, and up-regulate genes involved in immune tolerance through TLR1/2 engagement. 

​

These myeloid cells are long-lasting and exude potent anti-inflammatory effects.

​

​

Lupus nephritis & SER-101

Lupus nephritis is a kidney disorder that afflicts most lupus patients. It is a serious condition that can result in end-stage renal disease if not properly treated.

​

Current therapies target patient lymphocyte activity as an attempt to avoid further destruction of the kidney. We believe the innate system, particularly myeloid cells, play a major role in lupus nephritis.

​

Instead of adding another immune suppressant, SerenityBio hypothesizes that targeting myeloid cells using HspB5 will increase response rates and improve effectiveness of the standard of care.

​